Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Skin Substitute Access and Payment Reform Act
Client: ORGANOGENESIS INC. · Firm: ORGANOGENESIS INC.
Medicare reimbursement policy for chronic wound healing products, including Local Coverage Determinations Physician Fee Schedule regulations regarding reimbursement for chronic wound healing products Hospital Outpatient Prospective Payment regulations regarding reimbursement for chronic wound healing products (CY2026) H.R. 5768 and S. 2561 (Skin Substitute Access and Payment Reform Act of 2025), entire bill H.R. 6852 (Advanced Wound Care and Regenerative Medicine Access and Reform Act), entire bill
Skin Substitute Access and Payment Reform Act
Client: ORGANOGENESIS INC. · Firm: ORGANOGENESIS INC.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ORGANOGENESIS INC. via ORGANOGENESIS INC.
2026 · third_quarter · Q3
FDA policy on chronic wound healing products
Medicare reimbursement policy for chronic wound healing products, including Local Coverage Determinations Physician Fee Schedule regulations regarding reimbursement for chronic wound healing products Hospital Outpatient Prospective Payment regulations regarding reimbursement for chronic wound healing products (CY2026) H.R. 5768 and S. 2561 (Skin Substitute Access and Payment Reform Act of 2025), entire bill H.R. 6852 (Advanced Wound Care and Regenerative Medicine Access and Reform Act), entire bill
Source: Senate LDA
Medicare reimbursement policy for chronic wound healing products, including Local Coverage Determinations Physician Fee Schedule regulations regarding reimbursement for chronic wound healing products Hospital Outpatient Prospective Payment regulations regarding reimbursement for chronic wound healing products (CY2026) H.R. 5768 and S. 2561 (Skin Substitute Access and Payment Reform Act of 2025), entire bill H.R. 6852 (Advanced Wound Care and Regenerative Medicine Access and Reform Act), entire bill
Skin Substitute Access and Payment Reform Act
Client: ORGANOGENESIS INC. · Firm: ORGANOGENESIS INC.
Medicare reimbursement policy for chronic wound healing products, including Local Coverage Determinations Physician Fee Schedule regulations regarding reimbursement for chronic wound healing products Hospital Outpatient Prospective Payment regulations regarding reimbursement for chronic wound healing products (CY2026) H.R. 5768 and S. 2561 (Skin Substitute Access and Payment Reform Act of 2025), entire bill H.R. 6852 (Advanced Wound Care and Regenerative Medicine Access and Reform Act), entire bill
Advanced Wound Care and Regenerative Medicine Access and Reform Act
Client: ORGANOGENESIS INC. · Firm: ORGANOGENESIS INC.
Medicare reimbursement policy for chronic wound healing products, including Local Coverage Determinations Physician Fee Schedule regulations regarding reimbursement for chronic wound healing products Hospital Outpatient Prospective Payment regulations regarding reimbursement for chronic wound healing products (CY2026) H.R. 5768 and S. 2561 (Skin Substitute Access and Payment Reform Act of 2025), entire bill H.R. 6852 (Advanced Wound Care and Regenerative Medicine Access and Reform Act), entire bill
Advanced Wound Care and Regenerative Medicine Access and Reform Act
Client: ORGANOGENESIS INC. · Firm: ORGANOGENESIS INC.
Medicare reimbursement policy for chronic wound healing products, including Local Coverage Determinations Physician Fee Schedule regulations regarding reimbursement for chronic wound healing products Hospital Outpatient Prospective Payment regulations regarding reimbursement for chronic wound healing products (CY2026) H.R. 5768 and S. 2561 (Skin Substitute Access and Payment Reform Act of 2025), entire bill H.R. 6852 (Advanced Wound Care and Regenerative Medicine Access and Reform Act), entire bill
Advanced Wound Care and Regenerative Medicine Access and Reform Act
Client: ORGANOGENESIS INC. · Firm: ORGANOGENESIS INC.
Medicare reimbursement policy for chronic wound healing products, including Local Coverage Determinations Physician Fee Schedule regulations regarding reimbursement for chronic wound healing products Hospital Outpatient Prospective Payment regulations regarding reimbursement for chronic wound healing products (CY2026) H.R. 5768 and S. 2561 (Skin Substitute Access and Payment Reform Act of 2025), entire bill H.R. 6852 (Advanced Wound Care and Regenerative Medicine Access and Reform Act), entire bill
Skin Substitute Access and Payment Reform Act of 2025
Client: ORGANOGENESIS INC. · Firm: ORGANOGENESIS INC.
Medicare reimbursement policy for chronic wound healing products, including Local Coverage Determinations Physician Fee Schedule regulations regarding reimbursement for chronic wound healing products Hospital Outpatient Prospective Payment regulations regarding reimbursement for chronic wound healing products (CY2026) H.R. 5768 and S. 2561 (Skin Substitute Access and Payment Reform Act of 2025), entire bill H.R. 6852 (Advanced Wound Care and Regenerative Medicine Access and Reform Act), entire bill
Skin Substitute Access and Payment Reform Act of 2025
Client: ORGANOGENESIS INC. · Firm: ORGANOGENESIS INC.
Medicare reimbursement policy for chronic wound healing products, including Local Coverage Determinations Physician Fee Schedule regulations regarding reimbursement for chronic wound healing products Hospital Outpatient Prospective Payment regulations regarding reimbursement for chronic wound healing products (CY2026) H.R. 5768 and S. 2561 (Skin Substitute Access and Payment Reform Act of 2025), entire bill H.R. 6852 (Advanced Wound Care and Regenerative Medicine Access and Reform Act), entire bill
Skin Substitute Access and Payment Reform Act of 2025
Client: ORGANOGENESIS INC. · Firm: ORGANOGENESIS INC.
Medicare reimbursement policy for chronic wound healing products, including Local Coverage Determinations Physician Fee Schedule regulations regarding reimbursement for chronic wound healing products Hospital Outpatient Prospective Payment regulations regarding reimbursement for chronic wound healing products (CY2026) H.R. 5768 and S. 2561 (Skin Substitute Access and Payment Reform Act of 2025), entire bill H.R. 6852 (Advanced Wound Care and Regenerative Medicine Access and Reform Act), entire bill
Skin Substitute Access and Payment Reform Act of 2025
Client: ORGANOGENESIS INC. · Firm: ORGANOGENESIS INC.
Medicare reimbursement policy for chronic wound healing products, including Local Coverage Determinations Physician Fee Schedule regulations regarding reimbursement for chronic wound healing products Hospital Outpatient Prospective Payment System regulations regarding reimbursement for chronic wound healing products (CY2026) S. 2561 (Skin Substitute Access and Payment Reform Act of 2025), entire bill
Food and Drug Administration policy on chronic wound healing products S. 4348 (FDASLA Act of 2002), regarding Food and Drug Administration policy on chronic wound healing products H.R. 7667 (Food and Drug Amendments of 2022), regarding Food and Drug Administration policy on chronic wound healing products H.R. 2617 (Consolidated Appropriations Act, 2023), Division FF, Title III, regarding Food and Drug Administration policy on chronic wound healing products
Food and Drug Administration policy on chronic wound healing products H.R. 6000 (Cures 2.0 Act), Title III, regarding Food and Drug Administration policy on chronic wound healing products
Food and Drug Administration policy on chronic wound healing products H.R. 6000 (Cures 2.0 Act), Title III, regarding Food and Drug Administration policy on chronic wound healing products S.4348 (FDASLA Act of 2022), regarding FDA policy on chronic wound healing products H.R. 7667 (Food and Drug Amendments of 2022), regarding FDA policy on chronic wound healing products
Food and Drug Administration policy on chronic wound healing products H.R. 6000 (Cures 2.0 Act), Title III, regarding Food and Drug Administration policy on chronic wound healing products S.4348 (FDASLA Act of 2022), regarding FDA policy on chronic wound healing products H.R. 7667 (Food and Drug Amendments of 2022), regarding FDA policy on chronic wound healing products
Food and Drug Administration policy on chronic wound healing products S. 4348 (FDASLA Act of 2002), regarding Food and Drug Administration policy on chronic wound healing products H.R. 7667 (Food and Drug Amendments of 2022), regarding Food and Drug Administration policy on chronic wound healing products H.R. 2617 (Consolidated Appropriations Act, 2023), Division FF, Title III, regarding Food and Drug Administration policy on chronic wound healing products
Food and Drug Administration policy on chronic wound healing products H.R. 6000 (Cures 2.0 Act), Title III, regarding Food and Drug Administration policy on chronic wound healing products S.4348 (FDASLA Act of 2022), regarding FDA policy on chronic wound healing products H.R. 7667 (Food and Drug Amendments of 2022), regarding FDA policy on chronic wound healing products
Protecting Access to Innovation During COVID–19 Act
Client: ORGANOGENESIS INC. · Firm: ORGANOGENESIS INC.
Medicare reimbursement policy for chronic wound healing products Hospital Outpatient Prospective Payment System proposed regulations regarding reimbursement for chronic would healing product S. 4295 (Public Health Emergency Pass-Through Payment Fairness Act of 2020), all provisions H.R. 8624 (Protecting Access to Innovation During COVID-19 Act), all provisions
Public Health Emergency Pass-Through Payment Fairness Act of 2020
Client: ORGANOGENESIS INC. · Firm: ORGANOGENESIS INC.
Medicare reimbursement policy for chronic wound healing products Hospital Outpatient Prospective Payment System proposed regulations regarding reimbursement for chronic would healing product S. 4295 (Public Health Emergency Pass-Through Payment Fairness Act of 2020), all provisions H.R. 8624 (Protecting Access to Innovation During COVID-19 Act), all provisions
Further Consolidated Appropriations Act, 2020
Client: ORGANOGENESIS INC. · Firm: ORGANOGENESIS INC.
Medical device excise tax H.R.2207 and S.692 (Protect Medical Innovation Act of 2019), all provisions H.R. 1865 (Further Consolidated Appropriations Act, 2020), Division N, Title I, Section 501, regarding medical device excise tax
Protect Medical Innovation Act of 2019
Client: ORGANOGENESIS INC. · Firm: ORGANOGENESIS INC.
Medical device excise tax H.R.2207 and S.692 (Protect Medical Innovation Act of 2019), all provisions H.R. 1865 (Further Consolidated Appropriations Act, 2020), Division N, Title I, Section 501, regarding medical device excise tax
Protect Medical Innovation Act of 2019
Client: ORGANOGENESIS INC. · Firm: ORGANOGENESIS INC.
Medical device excise tax H.R.2207 and S.692 (Protect Medical Innovation Act of 2019), all provisions
Protect Medical Innovation Act of 2019
Client: ORGANOGENESIS INC. · Firm: ORGANOGENESIS INC.
Medical device excise tax H.R.2207 and S.692 (Protect Medical Innovation Act of 2019), all provisions
Medical device excise tax H.R.2207 and S.692 (Protect Medical Innovation Act of 2019), all provisions
Medical device excise tax H.R.2207 and S.692 (Protect Medical Innovation Act of 2019), all provisions
Medical device excise tax H.R.2207 and S.692 (Protect Medical Innovation Act of 2019), all provisions H.R. 1865 (Further Consolidated Appropriations Act, 2020), Division N, Title I, Section 501, regarding medical device excise tax
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANOGENESIS INC. via ORGANOGENESIS INC.
2026 · second_quarter · Q2
FDA policy on chronic wound healing products
Medicare reimbursement policy for chronic wound healing products, including Local Coverage Determinations Physician Fee Schedule regulations regarding reimbursement for chronic wound healing products Hospital Outpatient Prospective Payment regulations regarding reimbursement for chronic wound healing products (CY2026) H.R. 5768 and S. 2561 (Skin Substitute Access and Payment Reform Act of 2025), entire bill H.R. 6852 (Advanced Wound Care and Regenerative Medicine Access and Reform Act), entire bill
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANOGENESIS INC. via ORGANOGENESIS INC.
2026 · first_quarter · Q1
Medicare reimbursement policy for chronic wound healing products, including Local Coverage Determinations Physician Fee Schedule regulations regarding reimbursement for chronic wound healing products Hospital Outpatient Prospective Payment regulations regarding reimbursement for chronic wound healing products (CY2026) H.R. 5768 and S. 2561 (Skin Substitute Access and Payment Reform Act of 2025), entire bill H.R. 6852 (Advanced Wound Care and Regenerative Medicine Access and Reform Act), entire bill
FDA policy on chronic wound healing products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANOGENESIS INC. via ORGANOGENESIS INC.
2025 · fourth_quarter · Q4
Medicare reimbursement policy for chronic wound healing products, including Local Coverage Determinations Physician Fee Schedule regulations regarding reimbursement for chronic wound healing products
FDA policy on chronic wound healing products
Discussion around new company manufacturing facilities located in Smithfield, Rhode Island.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANOGENESIS INC. via ORGANOGENESIS INC.
2025 · third_quarter · Q3
Medicare reimbursement policy for chronic wound healing products, including Local Coverage Determinations Physician Fee Schedule regulations regarding reimbursement for chronic wound healing products Hospital Outpatient Prospective Payment System regulations regarding reimbursement for chronic wound healing products (CY2026) S. 2561 (Skin Substitute Access and Payment Reform Act of 2025), entire bill
FDA policy on chronic wound healing products
Discussion around new company manufacturing facilities located in Smithfield, Rhode Island.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANOGENESIS INC. via ORGANOGENESIS INC.
2025 · second_quarter · Q2
Medicare reimbursement policy for chronic wound healing products, including Local Coverage Determinations Physician Fee Schedule regulations regarding reimbursement for chronic wound healing products
FDA policy on chronic wound healing products
Discussion around new company manufacturing facilities located in Smithfield, Rhode Island.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANOGENESIS INC. via ORGANOGENESIS INC.
2025 · first_quarter · Q1
Medicare reimbursement policy for chronic wound healing products, including Local Coverage Determinations Physician Fee Schedule regulations regarding reimbursement for chronic wound healing products
FDA policy on chronic wound healing products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANOGENESIS INC. via ORGANOGENESIS INC.
2024 · fourth_quarter · 4A
Discussion of potential new manufacturing facility in Smithfield, Rhode Island for wound care products.
Food and Drug Administration policy on chronic wound healing products
Medicare reimbursement policy for chronic wound healing products, including Local Coverage Determinations Physician Fee Schedule regulations regarding reimbursement for chronic wound healing products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANOGENESIS INC. via ORGANOGENESIS INC.
2024 · fourth_quarter · Q4
Food and Drug Administration policy on chronic wound healing products
Medicare reimbursement policy for chronic wound healing products, including Local Coverage Determinations Physician Fee Schedule regulations regarding reimbursement for chronic wound healing products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANOGENESIS INC. via ORGANOGENESIS INC.
2024 · third_quarter · Q3
Food and Drug Administration policy on chronic wound healing products
Medicare reimbursement policy for chronic wound healing products, including Local Coverage Determinations Physician Fee Schedule regulations regarding reimbursement for chronic wound healing products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANOGENESIS INC. via ORGANOGENESIS INC.
2024 · second_quarter · Q2
Food and Drug Administration policy on chronic wound healing products
Medicare reimbursement policy for chronic wound healing products, including Local Coverage Determinations Physician Fee Schedule regulations regarding reimbursement for chronic wound healing products
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ORGANOGENESIS INC. via ORGANOGENESIS INC.
2024 · first_quarter · Q1
Medicare reimbursement policy for chronic wound healing products, including Local Coverage Determinations Physician Fee Schedule regulations regarding reimbursement for chronic wound healing products
Food and Drug Administration policy on chronic wound healing products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANOGENESIS INC. via ORGANOGENESIS INC.
2023 · fourth_quarter · Q4
Food and Drug Administration policy on chronic wound healing products
Medicare reimbursement policy for chronic wound healing products, including Local Coverage Determinations Physician Fee Schedule regulations regarding reimbursement for chronic wound healing products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANOGENESIS INC. via ORGANOGENESIS INC.
2023 · third_quarter · Q3
Medicare reimbursement policy for chronic wound healing products, including Local Coverage Determinations Physician Fee Schedule regulations regarding reimbursement for chronic wound healing products
Food and Drug Administration policy on chronic wound healing products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANOGENESIS INC. via ORGANOGENESIS INC.
2023 · second_quarter · Q2
Medicare reimbursement policy for chronic wound healing products Physician Fee Schedule regulations regarding reimbursement for chronic wound healing products
Food and Drug Administration policy on chronic wound healing products
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
ORGANOGENESIS INC. via ORGANOGENESIS INC.
2023 · first_quarter · Q1
Food and Drug Administration policy on chronic wound healing products
Medicare reimbursement policy for chronic wound healing products Physician Fee Schedule regulations regarding reimbursement for chronic wound healing products
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ORGANOGENESIS INC. via ORGANOGENESIS INC.
2022 · fourth_quarter · Q4
Medicare reimbursement policy for chronic wound healing products Physician Fee Schedule regulations regarding reimbursement for chronic wound healing product
Food and Drug Administration policy on chronic wound healing products S. 4348 (FDASLA Act of 2002), regarding Food and Drug Administration policy on chronic wound healing products H.R. 7667 (Food and Drug Amendments of 2022), regarding Food and Drug Administration policy on chronic wound healing products H.R. 2617 (Consolidated Appropriations Act, 2023), Division FF, Title III, regarding Food and Drug Administration policy on chronic wound healing products
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ORGANOGENESIS INC. via ORGANOGENESIS INC.
2022 · third_quarter · Q3
Medicare reimbursement policy for chronic wound healing products Hospital Outpatient Prospective Payment System proposed regulation regarding reimbursement for chronic wound healing product Physician Fee Schedule regulations regarding reimbursement for chronic wound healing product
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANOGENESIS INC. via ORGANOGENESIS INC.
2022 · second_quarter · Q2
Medicare reimbursement policy for chronic wound healing products Hospital Outpatient Prospective Payment System proposed regulation regarding reimbursement for chronic wound healing product
Food and Drug Administration policy on chronic wound healing products H.R. 6000 (Cures 2.0 Act), Title III, regarding Food and Drug Administration policy on chronic wound healing products S.4348 (FDASLA Act of 2022), regarding FDA policy on chronic wound healing products H.R. 7667 (Food and Drug Amendments of 2022), regarding FDA policy on chronic wound healing products
Department of Defense research and development funding regarding regenerative medicine products
ORGANOGENESIS INC. via ORGANOGENESIS INC.
2022 · first_quarter · Q1
Food and Drug Administration policy on chronic wound healing products H.R. 6000 (Cures 2.0 Act), Title III, regarding Food and Drug Administration policy on chronic wound healing products
Department of Defense research and development funding regarding regenerative medicine products
Medicare reimbursement policy for chronic wound healing products Hospital Outpatient Prospective Payment System proposed regulation regarding reimbursement for chronic wound healing product
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANOGENESIS INC. via ORGANOGENESIS INC.
2021 · fourth_quarter · 4A
Department of Defense research and development funding regarding regenerative medicine products
Medicare reimbursement policy for chronic wound healing products Hospital Outpatient Prospective Payment System proposed regulation regarding reimbursement for chronic wound healing product
Food and Drug Administration policy on chronic wound healing products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANOGENESIS INC. via ORGANOGENESIS INC.
2021 · fourth_quarter · Q4
Food and Drug Administration policy on chronic wound healing products
Department of Defense research and development funding regarding regenerative medicine products
Medicare reimbursement policy for chronic wound healing products Hospital Outpatient Prospective Payment System proposed regulation regarding reimbursement for chronic wound healing product
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANOGENESIS INC. via ORGANOGENESIS INC.
2021 · third_quarter · Q3
Medicare reimbursement policy for chronic wound healing products Hospital Outpatient Prospective Payment System proposed regulation regarding reimbursement for chronic wound healing product
Food and Drug Administration policy on chronic wound healing products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANOGENESIS INC. via ORGANOGENESIS INC.
2021 · second_quarter · Q2
Food and Drug Administration policy on chronic wound healing products
Medicare reimbursement policy for chronic wound healing products Hospital Outpatient Prospective Payment System proposed regulation regarding reimbursement for chronic wound healing product
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANOGENESIS INC. via ORGANOGENESIS INC.
2021 · first_quarter · Q1
Medicare reimbursement policy for chronic wound healing products Hospital Outpatient Prospective Payment System proposed regulation regarding reimbursement for chronic wound healing product
Food and Drug Administration policy on chronic wound healing products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANOGENESIS INC. via ORGANOGENESIS INC.
2020 · fourth_quarter · Q4
Medicare reimbursement policy for chronic wound healing products Hospital Outpatient Prospective Payment System proposed regulations regarding reimbursement for chronic would healing product S. 4295 (Public Health Emergency Pass-Through Payment Fairness Act of 2020), all provisions H.R. 8624 (Protecting Access to Innovation During COVID-19 Act), all provisions
ORGANOGENESIS INC. via ORGANOGENESIS INC.
2020 · second_quarter · Q2
Medicare reimbursement policy for chronic wound healing products Hospital Outpatient Prospective Payment System proposed regulations regarding reimbursement for chronic wound healing product
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANOGENESIS INC. via ORGANOGENESIS INC.
2020 · first_quarter · Q1
Medicare reimbursement policy for chronic wound healing products Hospital Outpatient Prospective Payment System proposed regulations regarding reimbursement for chronic wound healing product
Federal research and development funding regarding regenerative medicine products
Procurement of chronic wound healing products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANOGENESIS INC. via ORGANOGENESIS INC.
2019 · fourth_quarter · Q4
Federal research and development funding regarding regenerative medicine products
Medicare reimbursement policy for chronic wound healing products Hospital Outpatient Prospective Payment System proposed regulations regarding reimbursement for chronic wound healing product
Medical device excise tax H.R.2207 and S.692 (Protect Medical Innovation Act of 2019), all provisions H.R. 1865 (Further Consolidated Appropriations Act, 2020), Division N, Title I, Section 501, regarding medical device excise tax
ORGANOGENESIS INC. via ORGANOGENESIS INC.
2019 · third_quarter · Q3
Procurement of chronic wound healing products
Federal research and development funding regarding regenerative medicine products
Medicare reimbursement policy for chronic wound healing products Hospital Outpatient Prospective Payment System proposed regulations regarding reimbursement for chronic wound healing product
ORGANOGENESIS INC. via ORGANOGENESIS INC.
2019 · second_quarter · Q2
Medical device excise tax H.R.2207 and S.692 (Protect Medical Innovation Act of 2019), all provisions
Federal research and development funding regarding regenerative medicine products
Procurement of chronic wound healing products
ORGANOGENESIS INC. via ORGANOGENESIS INC.
2019 · second_quarter · RA
Medicare reimbursement policy including hospital outpatient prospective payment system (HOPPS) rule; Medical device tax repeal; Food and Drug Administration policy on regenerative medicine and chronic wound healing products; VA procurement; Federal research and development funding regarding regenerative medicine and chronic wound care products; Biotechnology/Medical Device related legislation
Medicare reimbursement policy including hospital outpatient prospective payment system (HOPPS) rule; Medical device tax repeal; Food and Drug Administration policy on regenerative medicine and chronic wound healing products; VA procurement; Federal research and development funding regarding regenerative medicine and chronic wound care products; Biotechnology/Medical Device related legislation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Food and Drug Administration policy on chronic wound healing products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Food and Drug Administration policy on chronic wound healing products
Medical device excise tax H.R.2207 and S.692 (Protect Medical Innovation Act of 2019), all provisions
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Food and Drug Administration policy on chronic wound healing products
Medicare reimbursement policy for chronic wound healing products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Medicare reimbursement policy including hospital outpatient prospective payment system (HOPPS) rule; Medical device tax repeal; Food and Drug Administration policy on regenerative medicine and chronic wound healing products; VA procurement; Federal research and development funding regarding regenerative medicine and chronic wound care products; Biotechnology/Medical Device related legislation
Medicare reimbursement policy including hospital outpatient prospective payment system (HOPPS) rule; Medical device tax repeal; Food and Drug Administration policy on regenerative medicine and chronic wound healing products; VA procurement; Federal research and development funding regarding regenerative medicine and chronic wound care products; Biotechnology/Medical Device related legislation
Medicare reimbursement policy including hospital outpatient prospective payment system (HOPPS) rule; Medical device tax repeal; Food and Drug Administration policy on regenerative medicine and chronic wound healing products; VA procurement; Federal research and development funding regarding regenerative medicine and chronic wound care products; Biotechnology/Medical Device related legislation